Skip to content

Multicatheter interstitial brachytherapy (MIBT) based accelerated partial breast irradiation (APBI) - dosimetric comparison with external beam radiotherapy and report on early outcomes in terms of toxicity and local control

Multicatheter interstitial brachytherapy (MIBT) based accelerated partial breast irradiation (APBI) - dosimetric comparison with external beam radiotherapy and report on early outcomes in terms of toxicity and local control

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2018/01/011300
Enrollment
48
Registered
2018-01-12
Start date
Unknown
Completion date
Unknown
Last updated
2021-11-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: null- Post Surgery For Breast Cancer

Interventions

None listed

Sponsors

None listed

Eligibility

Inclusion criteria

Inclusion criteria: 1. Patients eligible and willing to undergo APBI. The American Society for Radiation Oncology (ASTRO) recommendations for APBI include all of the following: 1. Age > 50 years 2. Tumor 3. Histology: IDC Invasive Ductal Carcinoma 4. Negative Lymph node status 5. Negative resection margins 6. No evidence of Lympho-vascular invasion 7. No evidence of Extracapsular invasion 2. In addition, patients with features considered to be cautionary by guidelines (such as ages between 40-50 years, high grade disease, evidence of LVSI, etc.) who have been informed about the pros and cons of APBI and have voluntarily preferred undergoing the procedure will be taken up

Exclusion criteria

Exclusion criteria: 1. Patients unwilling for APBI 2. Positive surgical resection margins. 3. Other definite contraindications for APBI such as multiple nodes positive, neoadjuvant chemotherapy, multifocal/multicentric disease, etc. 4. Incomplete/inadequate information on relevant Organs at Risk on Planning CT images. 5. Patients in whom the implant was deemed as unacceptable (eg: gross miss of surgical cavity).

Design outcomes

Primary

MeasureTime frame
To dosimetrically compare normal tissue exposure and tumor coverage of IMRT among patients treated with MIBT based APBITimepoint: 3 months from ethics committee clearance

Secondary

MeasureTime frame
1. To evaluate local control rate following MIBT-APBI 2. To analyse toxicities of treatment 3. Record physician and patient perceived cosmetic outcomes of treatmentTimepoint: 3 months from ethics committee clearance

Countries

India

Contacts

Public ContactKiron G

KMC MANIPAL

tk.sharan@gmail.com9448625116

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026